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Abstract
The presence of elevated glucose concentrations in diabetes is a metabolic change that leads to an increase in the
amount of non-enzymatic glycation that occurs for serum proteins. One protein that is affected by this process is
the main serum protein, human serum albumin (HSA), which is also an important carrier agent for many drugs
and fatty acids in the circulatory system. Sulfonylurea drugs, used to treat type 2 diabetes, are known to have significant binding to HSA. This study employed ultrafiltration and high-performance affinity chromatography to examine the effects of HSA glycation on the interactions of several sulfonylurea drugs (i.e., acetohexamide, tolbutamide and gliclazide) with fatty acids, whose concentrations in serum are also affected by diabetes. Similar overall
changes in binding were noted for these drugs with normal HSA or glycated HSA and in the presence of the fatty
acids. For most of the tested drugs, the addition of physiological levels of the fatty acids to normal HSA and glycated HSA produced weaker binding. At low fatty acid concentrations, many of these systems followed a direct
competition model while others involved a mixed-mode interaction. In some cases, there was a change in the interaction mechanism between normal HSA and glycated HSA, as seen with linoleic acid. Systems with only direct
competition also gave notable changes in the affinities of fatty acids at their sites of drug competition when comparing normal HSA and glycated HSA. This research demonstrated the importance of considering how changes
in the concentrations and types of metabolites (e.g., in this case, glucose and fatty acids) can alter the function of a
protein such as HSA and its ability to interact with drugs or other agents.
Keywords: Diabetes, drug-protein binding, fatty acids, glycation, high-performance affinity chromatography, human serum albumin, sulfonylurea drugs, ultrafiltration

the reported reference range for glycated HSA in normal
individuals is typically 0.6-3%, with this amount increasing
by two- to five-fold during type 2 diabetes [14, 15].
The glycation of HSA has been of recent interest due to
the importance of this protein as a carrier agent for many
drugs and endogenous compounds in the circulatory system [10-14]. Sulfonylurea drugs are a set of pharmaceutical agents that are known to have significant binding to
HSA [11, 14, 16-25]. These drugs are used to treat type 2
diabetes by stimulating the secretion of insulin [16]. Some
common sulfonylurea drugs are acetohexamide, tolbutamide and gliclazide (see structures in Figure 1). These
drugs are all highly bound in blood to HSA and have
been shown to have significant interactions at a set of high
affinity sites that include both of the major drug interaction sites of this protein: Sudlow sites I and II, as shown
in Figure 2 [16-23]. In addition, recent studies have found
that glycation can alter the binding of sulfonylurea drugs
with HSA [20-25]. The association equilibrium constants
for the high affinity interactions of these drugs with normal HSA, and with HSA that has glycation levels similar
to those seen in diabetes, have been reported to be in the
range of 1.3-4.2 × 105 M–1 for acetohexamide, 0.87-1.2 × 105
M–1 for tolbutamide, and 0.7-1.0 × 105 M–1 for gliclazide at
pH 7.4 and 37°C [19, 21-23].

Introduction
Diabetes has been estimated to affect 285 million people
worldwide and 24 million in the U.S. [1, 2]. The high blood
glucose concentrations that are characteristic of this metabolic disease are caused by a deficiency in insulin production or an impaired efficiency in insulin action [1-3]. These
elevated concentrations of glucose are often combined with
other factors, such as high blood pressure and altered lipid
levels, which can lead to cardiovascular disease, kidney or
liver damage, and blindness [1-4]. Many of these complications are associated with the non-enzymatic glycation of
proteins [5].
Glycation is a process that is enhanced during diabetes. This process begins with the reaction of a free amine
group on a protein with an aldehyde group on a reducing
sugar, such as glucose, to form a reversible Schiff base. A
slow rearrangement of this Schiff base can produce a more
stable fructosamine residue, or Amadori product [6-8]. Numerous studies have indicated that glycation can produce
structural and functional modifications in proteins with
relatively long half-lives, such as collagen, lens crystalline,
and hemoglobin [4, 5, 8-10]. Glycation can also occur with
human serum albumin (HSA), the main protein in serum
[6, 7, 9-14]. For modern affinity-based detection methods,
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Figure 1. Structures of the sulfonylurea drugs and fatty acids that were examined in this study.

Figure 2. Structure of HSA, including the
regions that bind palmitic acid and the major
drug binding sites of this protein (i.e., Sudlow
sites I and II). This structure was generated
using Protein Data Bank (PDB) file ID: 1E7H
[33].

Another metabolic change that occurs during diabetes is
the presence of elevated concentrations of free fatty acids
in serum [26-28]. Several studies have noted that increased
levels of free fatty acids can contribute to the pathogenesis of hypertension, cardiovascular risk factors, and conditions such as atherosclerosis [29]. In addition, high glucose levels and elevated fatty acid concentrations in serum
have been correlated with impaired sensitivity, increased
inflammation, and oxidative stress, among other meta-

bolic complications [30, 31]. HSA binds to many fatty acids, some of which are shown in Figure 1 [32]. In addition,
it is known that some fatty acids can have direct competition with drugs or lead to allosteric effects during the binding of drugs and other solutes with HSA [14, 33-35]. There
are a number of binding regions for fatty acids on HSA,
as illustrated in Figure 2 [33, 35-39], with the strongest of
these interactions having association equilibrium constants
in the range of 105 to 108 M–1 [33, 39].
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A recent report used a chromatographic high-throughput screening method to compare the overall effects of
glycation and the presence of fatty acids on the binding of several sulfonylurea drugs with HSA [20]. It was
found that there was a significant increase in retention
(i.e., stronger binding) for drugs such as acetohexamide,
tolbutamide and gliclazide in going from normal HSA to
glycated HSA. It was also noted that the addition of low
levels of fatty acids led to lower binding for these drugs
with both normal HSA and glycated HSA. This current
study examined these effects further by using both ultrafiltration and high-performance affinity chromatography
(HPAC) [14, 40, 41]. Ultrafiltration was utilized to determine the overall effects of various fatty acids at physiological concentrations on the binding of acetohexamide,
tolbutamide and gliclazide with normal HSA and glycated HSA. Experiments based on HPAC and competition
experiments were used to examine these interactions in
more detail, particularly in the presence of low concentrations of fatty acids. The results of this study were then utilized to provide further clues as to how the interactions of
sulfonylurea drugs and fatty acids with HSA may change
during metabolic diseases such as diabetes.
Materials and Methods
Reagents
The HSA (essentially fatty acid free) and glycated HSA
used in the chromatographic studies (3.6 mol hexose/mol
HSA, essentially fatty acid free) [20] were from Sigma- Aldrich (St. Louis, MO, USA). The sulfonylurea drugs and
fatty acids that were examined in this study (see summary
in Figure 1) were also obtained from Sigma-Aldrich. The
glycated HSA used in the ultrafiltration studies was prepared from normal HSA according to a previous method
[20, 21] and contained 3.4 mol hexose/mol HSA, as determined by using a fructosamine assay from Diazyme Laboratories (Poway, CA, USA). The modification levels that
were present in the glycated HSA samples were representative of what might be present during uncontrolled
or advanced diabetes [20-23]. Sterilized culture tubes (17
× 100 mm) and siliconized polypropylene microcentrifuge tubes (13 × 40 mm) were obtained from Fisher Scientific (Pittsburgh, PA, USA). Slide- A-Lyzer dialysis cassettes (7 kDa MW cutoff; 12–30 mL sample volume) were
purchased from Thermo Scientific (Rockford, IL, USA).
Econo-Pac 10 DG disposable desalting columns were acquired from Bio-Rad Laboratories (Hercules, CA, USA).
Nucleosil Si-300 silica (7 μm particle diameter, 300 Å pore
size) was obtained from Macherey-Nagel (Düren, Germany). Other chemicals were reagent grade or better. All
buffers and aqueous solutions were prepared using water
from a Nanopure water system (Barnstead, Dubuque, IA)
and were filtered using 0.2 μm GNWP nylon filters from
Millipore (Billerica, MA, USA).
Apparatus
Ultrafiltration was performed using Centrifree Micropartition devices (30 kDa MW cutoff, 0.15–1.0 mL sample capacity) from Amicon (Danvers, MA, USA) and a
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5702RH temperature-controlled centrifuge from Eppendorf
(New York, NY, USA) equipped with a fixed-angle centrifuge rotor from VWR (West Chester, PA, USA). Flow-injection analysis of the drug content in each filtrate was carried
out by using a Jasco 2000 HPLC system (Easton, MD, USA)
that contained a DG-2080-53 degasser, a PU- 2080 pump,
an AS-2057 autosampler equipped with a 100 μL sample
loop (operated in the partial loop injection mode), and a
UV-2075 absorbance detector. These system components
were controlled by a Jasco LC-Net II/ADC system and using EZ Chrom SI software (Scientific Software, Pleasanton,
CA, USA). The peaks detected in the injected samples were
integrated using PeakFit 4.12 (Sea-Solve Software, San Jose,
CA, USA). Non-linear regression of the data was carried
out by utilizing Data Fit 8.1.69 (Oakdale, PA, USA).
The system employed in the chromatographic measurements consisted of a Hitachi L-6000 pump (Pleasanton, CA,
USA), a ThermoSeparations SpectraSystem AS3000 autosampler (Waltham, MA, USA) with a 10 μL sample loop,
and a Waters 481 UV detector (Milford, MA, USA). Detection was performed at 248 nm for acetohexamide and at
226 nm for gliclazide and tolbutamide. The columns were
kept at 37 (± 0.1) °C by using a water jacket from Fisher
Scientific and a 2067 CH/P recirculating water bath from
Forma Scientific (Marietta, OH, USA). Data were acquired
using Lab-View 8.0 (National Instruments, Austin, TX,
USA) and processed using PeakFit 4.12.
Ultrafiltration Studies
All solutions of drugs, fatty acids and proteins used in
the ultrafiltration studies were prepared in pH 7.4, 0.067 M
potassium phosphate buffer. To study the effect of fatty acids on the binding of sulfonylurea drugs to HSA and glycated HSA, fatty acid solutions were prepared over the
following ranges of concentrations, which included the
typical physiological levels of these solutes and concentrations that can be found in serum during diabetes [42-44]:
lauric acid (0-16 μM), linoleic acid (0-300 μM), myristic acid
(0-220 μM), oleic acid (0-600 μM), palmitic acid (0-400 μM),
and stearic acid (0-80 μM). The samples for these fatty acid
studies were prepared by mixing 0.25 mL of a fatty acid solution with 0.5 mL of an HSA or glycated HSA solution,
giving a final protein concentration of 260–290 μM. The
fatty acid/protein mixture was incubated at 37ºC in a water bath for 24 h, followed by the addition of 0.5 mL of a
given drug at a final fixed concentration of 200 μM (Note:
this concentration represents a common therapeutic level
for acetohexamide and tolbutamide [45] and allowed for
easy detection of the free drug fractions). Although sulfonylureas are weak acids with pKa values in the range of 5.2
to 6.2, all of the tested drug solutions had a pH that differed by less than 0.05 units from pH 7.4; these pH values
were found to be quite stable and to change by less than
0.05 units over the entire course of the binding studies [2123]. The drug/fatty acid/protein mixture was incubated
at 37ºC for 45 min in a water bath; the use of longer incubation times up to 90 min did not produce any significant
change in the final results.
Prior to ultrafiltration, the membrane in each ultrafiltration device was rinsed three times with deionized water and pH 7.4, 0.067 M potassium phosphate buffer to re-
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duce interferences by any contaminants or preservatives
that may have been present. The ultrafiltration device was
spun for at least 15 min at 1,500 ×g after rinsing to avoid dilution errors due to the presence of any remaining rinse solution in the device; the volume of rinse solution that remained after this step was less than ~10 μL.
The ultrafiltration experiments were carried out by
placing a 1 mL aliquot of each test mixture into a Centrifree micropartition device and spinning this mixture at
1,500 ×g for 25 min at 37 ºC. The filtrate was collected and
analyzed for its drug content by injecting 5 μL aliquots in
triplicate onto a flow-injection analysis system with no
column present. These injections were made at 0.5 mL/
min and in the presence of pH 7.4, 0.067 M potassium
phosphate buffer. The eluting drug fractions were monitored at 257 nm for acetohexamide and at 227 nm for tolbutamide or gliclazide. A background correction for any
contaminants or preservatives remaining in the filtrate
from the ultrafiltration device was made by carrying out
similar measurements on filtrates for 0.5 mL samples that
contained only HSA or glycated HSA in pH 7.4, 0.067 M
potassium phosphate buffer.
Chromatographic Studies
The normal HSA and glycated HSA columns were prepared by converting Nucleosil Si-300 silica into a diolbonded form and then using the Schiff base coupling
method, as described previously [19-21]. As noted in previous work, the immobilization of HSA by this approach
mainly occurs through the N-terminus or lysines that
are not located at Sudlow sites I and II [43] and has been
shown to provide columns containing immobilized normal
HSA or glycated HSA that are good models for the soluble
forms of these proteins [19-24]. These supports were found
by a bicinchoninic acid (BCA) protein assay to contain 25 (±
2) mg HSA or 15.4 (± 0.7) mg glycated HSA per g silica, as
determined in triplicate by using HSA as the standard and
diol-bonded silica as the blank. The supports were packed
into separate 2.0 cm × 2.1 mm I.D. columns at 3500 psi (24.1
MPa). A pH 7.4, 0.067 M potassium phosphate buffer was
used as the packing solution, and the columns were stored
in this buffer at 4°C when not in use. Control columns were
prepared in the same manner but with no protein being
added during the immobilization step. All columns were
used over the course of a few months and were found to
provide stable retention factors under these operating conditions [19-24].
The mobile phase used in the chromatographic-based
competition studies contained pH 7.4, 0.067 M phosphate
buffer or the same buffer plus a known concentration of the
fatty acid to be tested. The fatty acid concentrations that
were used were generally 100-fold lower than physiological levels or those seen in diabetes, which made it possible to monitor changes in the high affinity binding of the
fatty acids during the chromatographic studies [20, 4244]. The samples contained 5 μM of the desired drug in
the mobile phase, which was used as a tracer to probe any
changes in retention for the drug at its binding sites on
HSA [19, 22-24]. Under the conditions used in these studies, approximately 82-99% of the observed drug retention
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in the absence of any fatty acids should have been due to
interactions at Sudlow sites I and II [25]. These drug samples were injected in triplicate at 37oC and 0.5 mL/min.
No significant changes in retention occurred when using
slightly higher sample concentrations of the drugs, indicating that linear elution conditions were present, or when using slower flow rates for the chromatographic studies. Injections of 5 μM sodium nitrate (i.e., a non-retained solute
for HSA columns [19-24], which was detected at 205 nm)
were made to measure the void time of each column. Studies with the control column indicated that the tested drugs
had no significant non-specific retention to the support
(i.e., less than 3% of the total retention noted on the normal
HSA or glycated HSA columns).
Results and Discussion
Effects of Fatty Acids on the Overall Binding of Sulfonylurea Drugs to Normal or Glycated HSA
Ultrafiltration studies were used to first examine the
overall effects of glycation versus fatty acids on the binding of sulfonylureas to HSA. This method was utilized to
compare the changes in the free, or non-protein bound,
fraction of each drug, which was used as an index of the
total binding of these drugs with normal HSA or glycated
HSA. Some typical experimental results are provided in
Figure 3, which show how the measured free drug fractions changed for normal HSA as increasing concentrations of linoleic acid were added. Tables 1 and 2 summarize the changes in the free drug concentrations that were
obtained in these studies with normal HSA or glycated
HSA and in the absence or presence of various fatty acids that are commonly found in blood. In each case, both
normal concentrations (Table 1) and elevated concentrations (Table 2) of these fatty acids, as found during diabetes, were tested.
For most of the combinations of fatty acids, drugs and
types of HSA that were examined, the change in free drug
concentration that was measured as the fatty acid concentration was increased gave a reasonably good fit to a linear
model. Some examples of such fits are shown in Figure 3
for normal HSA and linoleic acid. In this figure, the correlation coefficients of the best-fit responses for acetohexamide,
gliclazide and tolbutamide were 0.784 (n = 8), 0.918 (n = 9),
and 0.931 (n = 9). Similar results were seen for most of the
other combinations of fatty acids, drugs and types of HSA
that were examined. The corresponding best-fit lines typically had a positive slope, with the only exception occurring for gliclazide in the presence of oleic acid and normal
HSA, as discussed in the next paragraph. There were also
a few situations in which a large initial change in free drug
concentration at low fatty acid conditions required the use
of a non-linear fit or a multi-linear fit to describe the data.
This type of behavior was observed when using normal
HSA and tolbutamide in the presence of oleic acid or stearic acid and acetohexamide in the presence of palmitic acid,
as well as for gliclazide and glycated HSA in the presence
of oleic acid. However, in each of these cases a net positive
slope was still obtained.
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Figure 3. Effect of increasing the concentration of linoleic acid on the free drug concentration of acetohexamide (■), gliclazide (♦)
and tolbutamide (▲) in the presence of fixed total concentrations of each drug and normal HSA. Each point represents the average of three measurements and the error bars represent a range of ± 1 S.D.
Table 1. Effects of Normal Concentrations of Fatty Acids on the Binding of Sulfonylurea Drugs to HSA and Glycated HSA
Change in Free Drug Concentrationa

		
Fatty Acid

Acetohexamide

Gliclazide

Tolbutamide

0.2-10%
0.04-2.6%b,c

0.03-2.1%b
0.1-7%

0.04-2.7%
0.02-1.0%b,c

Linoleic acid (20-93 μM)
Normal HSA
Glycated HSA

3.2-15%
6-29%c

5-24%
5-23%c

2.4-11%
8-38%

Myristic acid (3-24 μM)
Normal HSA
Glycated HSA

2.6-20%
1.0-8%c

0.6-4.6%b
0.3-2.5%c

0.04-0.3%b
0.5-4.2%c

Oleic acid (33-182 μM)
Normal HSA
Glycated HSA

17-93%
0.4-2.1%

-1.5-8%a
9-21%b

9-35%d
1.5-8%

Palmitic acid (25-171 μM)
Normal HSA
Glycated HSA

4.0-27%d
1.5-10%c

4.3-29%
1.3-9%

4.3-29%
5-36%c

0.6-5%
0.6-5%c

4.4-41%
1.5-14%

19-31%d
2.8-25%c

Lauric acid (0.1-6 μM)
Normal HSA
Glycated HSA

Stearic acid (6-57 μM)
Normal HSA
Glycated HSA

a. All of the indicated changes are relative to the free concentration measured for a drug in the absence of any fatty acid at pH 7.4
and 37°C; the given values represent an increase in the free drug concentration, except for the case of gliclazide in the presence
of oleic acid and normal HSA.
b. All changes in the free drug concentration, except those indicated by this footnote, were significantly different at the 95%
confidence level when comparing the results measured at the upper end of the normal fatty acid concentration range versus the
results obtained when no fatty acid was present.
c. All changes in the free drug concentration, except those indicated by this footnote, were significantly different at the 95%
confidence level when comparing the results measured at the upper end of the normal fatty acid concentration range for normal
HSA versus glycated HSA.
d. Non-linear regression or a combination of linear regions were used in this case because some curvature was noted in the
corresponding plot of free drug concentration versus fatty acid concentration.
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Table 2. Effects of Elevated Concentrations of Fatty Acids on the Binding of Sulfonylurea Drugs to HSA and Glycated HSA
Change in Free Drug Concentrationa

			
Fatty Acid
Lauric acid (up to 9 μM)
Normal HSA
Glycated HSA
Linoleic acid (up to 300 μM)
Normal HSA
Glycated HSA

Acetohexamide

Gliclazide

Tolbutamide

13%
3.8%b

3.1%
10%

3.9%
1.5%b,c

49%
94%

76%
76%c

36%
120%

Myristic acid (up to 43 μM)
Normal HSA
Glycated HSA
Oleic acid (up to 600 μM)
Normal HSA
Glycated HSA

37%
15%

8%
4.5%c

0.6%b
8%c

310%
7%

-27%a
36%

53%
27%

Palmitic acid (up to 400 μM)
Normal HSA
Glycated HSA

64%
23%

68%
21%

69%
85%

Stearic acid (up to 80 μM)
Normal HSA
Glycated HSA

8%
7%c

57%
20%

37%
36%c

a. All of the indicated changes are relative to the free concentration measured for a drug in the absence of any fatty acid at pH 7.4
and 37°C. Each of the given values represents an increase in the free drug concentration, except for the case of gliclazide in the
presence of oleic acid and normal HSA.
b. All changes in the free drug concentration, except those indicated by this footnote, were significantly different at the 95%
confidence level when comparing the results measured at the upper end of the elevated fatty acid concentration range versus the
results obtained when no fatty acid was present.
c. All changes in the free drug concentration, except those indicated by this footnote, were significantly different at the 95%
confidence level when comparing the results measured at the upper end of the normal fatty acid concentration range for normal
HSA versus glycated HSA.

The results in Table 1 and 2 show that almost all of the
tested combinations of drugs and fatty acids resulted in
an increase in free drug concentration, or weaker drug
binding, as the concentration of fatty acids was increased.
This general observation agrees with the previous screening studies that used trace amounts of the same drugs
along with immobilized preparations of normal HSA or
glycated HSA and nanomolar concentrations of the given
fatty acids [20]. This decrease in drug binding could be
produced by direct competition of a fatty acid with a drug
for binding sites or through negative allosteric interactions [34, 35]. The presence for either type of interaction
fits with the fact that some fatty acids may bind either at
or near Sudlow sites I and II, as illustrated for palmitic
acid in Figure 2. The only case in which different behavior
was noted occurred for gliclazide in the presence of oleic
acid and normal HSA, for which a decrease in free drug
concentration and stronger drug binding was seen as the
amount of added fatty acid was increased. This behavior
can occur if a positive allosteric effect is present during
the binding of a fatty acid and a drug with HSA [35].

It was noted that the same general changes in free drug
concentrations in the presence of fatty acids tended to
occur for each drug with normal HSA or glycated HSA.
This observation was again in agreement with the previous screening studies using immobilized forms of these
proteins [20]. Some differences did occur in the relative
size of the effects for normal versus glycated HSA (e.g.,
as seen in some of the results for linoleic acid and palmitic
acid); however, the most significant difference occurred in
the results for gliclazide and acetohexamide in the presence of oleic acid. For gliclazide that was combined with
normal HSA, a decrease in free drug concentration was
seen as the amount of oleic acid was increased, but for the
glycated HSA an increase in free drug concentration was
noted under otherwise identical conditions. For acetohexamide, a large increase in free drug concentration was
measured in the presence of oleic acid and normal HSA,
while only a small increase was seen for the same drug in
the presence of oleic acid and glycated HSA.
Myristic acid (i.e., a medium length saturated fatty
acid) gave only a small or moderate change in binding for
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each of the tested drugs even at elevated fatty acid levels
(i.e., less than 8% change for gliclazide and tolbutamide at
43 μM myristic acid, and a change of 37% or less for acetohexamide). Small or moderate changes in binding were
also noted for each drug in the presence of medium-tolong chain saturated fatty acids such as lauric acid (<13%
change) and stearic acid (<57% change). Larger changes in
binding were observed for these drugs in the presence of
linoleic acid (i.e., a long chain unsaturated fatty acid) and
palmitic acid (a long chain saturated fatty acid). Both of
these fatty acids have relatively high concentrations in serum and gave moderate-to-large changes in binding for
the sulfonylurea drugs (i.e., a 36-120% change and a 2185% change, respectively, at elevated fatty acid levels). All
of these general trends agree with those noted for immobilized normal HSA and glycated HSA at lower fatty acid
concentrations [20]. Oleic acid is an unsaturated long chain
fatty acid that also occurs at a relatively high concentration
in serum. The small-to-moderate changes in binding seen
in the presence of oleic acid for tolbutamide with normal
HSA and for all of the drugs in the presence of this fatty
acid and glycated HSA further agreed with the results in
Reference [20].
Effects of Low Levels of Fatty Acids on the Binding of Sulfonylurea Drugs with HSA
The next stage of this study used competition studies
and HPAC to more closely examine the changes in binding that occurred for sulfonylurea drugs in the presence of
fatty acids and normal HSA or glycated HSA. The analysis of these systems was simplified by using fatty acid concentrations that were up to 100-fold below the levels found
in serum, as employed previously in a screening study to
emphasize the initial, high affinity interactions for these
fatty acids with HSA [20]. In this current report these conditions were used to examine the competition of these fatty
acids with sulfonylurea drugs in a quantitative fashion and
to compare the types of interactions that were occurring on
normal HSA and glycated HSA between these fatty acids
and drugs. During these experiments, the retention time
(tR) for a small amount of an injected drug was measured
and used to calculate the retention factor for the same drug
(k) by using the relationship k = (tR – tM)/tM, where tM is
the elution time for a nonretained solution (e.g., sodium nitrate for the columns used in this study). Examples of some
typical chromatograms that are obtained through this approach for both normal HSA and glycated HSA columns
can be found in Reference [20].
In this study, the change in the retention factor for a
drug that was injected onto a normal HSA column or glycated HSA column was examined as various concentrations
of fatty acids were added to the mobile phase. As described
previously for other systems, the presence of no significant
changes in the value of k for a drug as the fatty acid concentration is increased would indicate that no competition or allosteric effects are occurring between the drug and fatty acid
on the column [40]. A decrease in k with an increase in the
concentration of a fatty acid may be caused by direct competition of these agents or through negative allosteric effects,
while an increase in k could be produced through positive
allosteric effects. A review of the equations and models that
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can be used to differentiate between these possible effects
can be found in References [40] & [41].
Tables 3-5 summarize the results for competition studies
in which small amounts of acetohexamide, tolbutamide or
gliclazide were injected onto columns that contained normal HSA or glycated HSA and various fatty acids in the
mobile phase. The overall trends noted in this study were
in agreement with Reference [20] and the results in the previous section, in which most of the combinations of fatty
acids and sulfonylurea drugs gave a decrease in binding
for both normal HSA and glycated HSA as the concentration of fatty acids in the mobile phase was increased. This
decrease in binding was indicated in the chromatographic
studies by a decrease in the retention time of the injected
drug and a decrease in its retention factor (k), or an increase in the value of 1/k, as the fatty acid concentration
was raised.
When plots were prepared of 1/k versus fatty acid concentration, many of these graphs gave a linear increase in
1/k under the conditions used in this study, as shown in
(Figure 4). As illustrated in this figure, and by the best-fit
parameters provided in the Supportive/Supplementary
Material, many of the combinations of drugs and fatty acids gave similar shifts in retention for normal HSA versus
glycated HSA. This similarity in trends suggested that the
same general regions and types of interactions between the
drugs and fatty acids were present in both the normal HSA
and glycated HSA. However, the glycated HSA also tended
to have a larger change in binding, which confirmed that
glycation could alter these interactions [14, 20-25].
The linear plots of 1/k versus fatty acid concentration
that were seen for many of the sulfonylurea drugs and
fatty acids suggested that some type of direct competition
was present between these solutes under these conditions,
as predicted by Equation (1) [40, 41].
KaI VM [I]
1
=
+
k
KaAmL

VM

KaAmL

(1)

According to Equation (1), a linear relationship would
be expected between 1/k for an injected drug (A) and the
concentration of a fatty acid (I) in the mobile phase for a
system that has direct competition at a single site or a cluster of sites with similar binding affinities for A and I [40,
46, 47], as occurs for sulfonylurea drugs at Sudlow sites I
and II [21-24]. The terms KaA and KaI in Equation (1) are the
association equilibrium constants (i.e., where Ka is the reciprocal of the dissociation equilibrium constant, Kd) for the
drug and fatty acid with an immobilized binding agent in
the column (e.g., normal HSA or glycated HSA), VM is the
column void volume, and mL is the moles of binding sites
in the column.
Based on Equation (1) it was possible to classify each
drug and fatty acid combination with regards to whether
the system involved direct competition or a mixed-mode
interaction (e.g., allosteric interactions plus direct competition). These classifications are provided in Tables 3-5. Although similar classifications were seen for normal HSA
and glycated HSA with the tested drugs and many of the
fatty acids, quite different behavior was seen in some cases.
For instance, lauric acid and linoleic acid gave mixed-mode
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Table 3. Change in the Reciprocal of the Retention Factor (1/k) for Acetohexamide in the Presence of Increasing Concentrations
of Fatty Acids Applied to Normal HSA and Glycated HSA Columns
Fatty Acid

Correlation Coefficienta

Type of Competitionb

Lauric acid (1.5-6 nM)
Normal HSA
Glycated HSA

r = 0.896 (n = 6)
r = 0.390 (n = 6)c

Mixed mode
Direct(?)c, KaI = 9.6 (± 11.4) × 106 M–1

Linoleic acid (100-250 nM)
Normal HSA
Glycated HSA

r = 0.941 (n = 6)
r = 0.977 (n = 7)

Mixed mode
Direct, KaI = 1.2 (± 0.1) × 106 M–1

Myristic acid (4-24 nM)
Normal HSA
Glycated HSA

r = 0.887 (n = 6)
r = 0.987 (n = 6)

Direct, KaI = 5.2 (± 1.4) × 106 M–1
Direct, KaI = 1.6 (± 0.1) × 107 M–1

Oleic acid (125-546 nM)
Normal HSA
Glycated HSA

r = 0.638 (n = 6)c
r = 0.500 (n = 7)c

Direct(?)c, KaI = 2.6 (± 1.6) × 105 M–1
Direct(?)c, KaI = 3.2 (± 2.4) × 104 M–1

Palmitic acid (100-400 nM)
Normal HSA
Glycated HSA

r = 0.928 (n = 6)
r = 0.966 (n = 7)

Direct, KaI = 3.8 (± 0.8) × 105 M–1
Direct(?)c, KaI = 2.0 (± 11.5) × 108 M–1

Stearic acid (10-80 nM)
Normal HSA
Glycated HSA

r = 0.854 (n = 7)
r = 0.946 (n = 8)

Direct, KaI = 1.0 (± 0.3) × 106 M
Direct, KaI = 3.3 (± 0.5) × 106 M–1

a. The correlation coefficients are those obtained for a plot made according to Equation (1).
b. The values in parentheses represent a range of ± 1 S.D. A mixed mode interaction (e.g., direct competition plus a positive
allosteric effect) was indicated in plots made according to Equation (1) by an initial decrease and then gradual increase in the
retention factor for the injected drug as the concentration of fatty acids in the mobile phase was increased. A decrease in the
retention factor for the drug when there was an increase in the concentration of the fatty acids could be produced by either a net
negative allosteric effect or direct competition; in this study, the overall fit of the results to Equation (1) generally suggested that
direct competition was present in most of these cases. In these latter cases, the apparent value of KaI for the fatty acid, as obtained
by using Equation (1), is provided.
c. The correlation coefficient obtained in this case was not significant at the 95% confidence level or, in the case of palmitic acid and
glycated HSA, the resulting value of KaI had a level of uncertainty that made it difficult to determine if direct competition was
present in the given system. The symbol “(?)” indicates that the variation in the data was too large or the change in the retention
factor was too small to obtain a reliable determination of exact type of interaction that was present or of the corresponding value
of KaI in the case of direct competition.
Table 4. Change in the Reciprocal of the Retention Factor (1/k) for Gliclazide in the Presence of Increasing Concentrations of
Fatty Acids Applied to Normal HSA and Glycated HSA Columns
Fatty Acid

Correlation Coefficienta

Type of Competitionb

Lauric acid (1.5-6 nM)
Normal HSA
Glycated HSA

r = 0.902 (n = 6)
r = 0.513 (n = 6)c

Mixed mode
Direct(?)c, KaI = 1.8 (± 1.5) × 107 M–1

Linoleic acid (100-250 nM)
Normal HSA
Glycated HSA

r = 0.961 (n = 7)
r = 0.972 (n = 7)

Mixed mode
Direct, KaI = 1.6 (± 0.2) × 106 M–1

Myristic acid (4-24 nM)
Normal HSA
Glycated HSA

r = 0.885 (n = 6)
r = 0.965 (n = 6)

Direct, KaI = 6.4 (± 1.7) × 106 M–1
Direct, KaI = 2.4 (± 0.3) × 107 M–1

Oleic acid (125-546 nM)
Normal HSA
Glycated HSA

r = 0.894 (n = 6)
r = 0.796 (n = 7)

Mixed mode
Direct, KaI = 6.2 (± 2.1) × 104 M–1
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Table 4, continued.
Fatty Acid

Correlation Coefficienta

Type of Competitionb

Palmitic acid (100-400 nM)
Normal HSA
Glycated HSA

r = 0.965 (n = 6)
r = 0.905 (n = 7)

Direct, KaI = 6.3 (± 0.9) × 105 M–1
Direct(?)c, KaI = 4.5 (± 10.2) × 107 M–1

Stearic acid (10-80 nM)
Normal HSA
Glycated HSA

r = 0.885 (n = 7)
r = 0.982 (n = 8)

Direct, KaI = 7.4 (± 1.8) × 105 M–1
Direct, KaI = 3.6 (± 0.3) × 106 M–1

a. The correlation coefficients are those obtained for a plot made according to Equation (1).
b. The values in parentheses represent a range of ± 1 S.D. A mixed mode interaction (e.g., direct competition plus a positive
allosteric effect) was indicated in plots made according to Equation (1) by an initial decrease and then gradual increase in the
retention factor for the injected drug as the concentration of fatty acids in the mobile phase was increased. A decrease in the
retention factor for the drug when there was an increase in the concentration of the fatty acids could be produced by either a net
negative allosteric effect or direct competition; in this study, the overall fit of the results to Equation (1) generally suggested that
direct competition was present in most of these cases. In these latter cases, the apparent value of KaI for the fatty acid, as obtained
by using Equation (1), is provided.
c. The correlation coefficient obtained in this case was not significant at the 95% confidence level or, in the case of palmitic acid and
glycated HSA, the resulting value of KaI had a level of uncertainty that made it difficult to determine if direct competition was
present in the given system. The symbol “(?)” indicates that the variation in the data was too large or the change in the retention
factor was too small to obtain a reliable determination of exact type of interaction that was present or of the corresponding value
of KaI in the case of direct competition.
Table 5. Change in the Reciprocal of the Retention Factor (1/k) for Tolbutamide in the Presence of Increasing Concentrations of
Fatty Acids Applied to Normal HSA and Glycated HSA Columns
Fatty Acid

Correlation Coefficienta

Type of Competitionb

Lauric acid (1.5-6 nM)
Normal HSA
Glycated HSA

r = 0.873 (n = 6)
r = 0.448 (n = 6)c

Mixed mode
Direct(?)c, KaI = 1.0 (± 1.0) × 107 M–1

Linoleic acid (100-250 nM)
Normal HSA
Glycated HSA

r = 0.954 (n = 7)
r = 0.979 (n = 7)

Mixed mode
Direct, KaI = 1.1 (± 0.1) × 106 M–1

Myristic acid (4-24 nM)
Normal HSA
Glycated HSA

r = 0.909 (n = 6)
r = 0.982 (n = 6)

Direct, KaI = 4.1 (± 0.9) × 106 M–1
Direct, KaI = 1.4 (± 0.1) × 107 M–1

Oleic acid (125-546 nM)
Normal HSA
Glycated HSA

r = 0.688 (n = 6)c
r = 0.901 (n = 7)

Direct(?)c, KaI = 3.8 (± 2.1) × 105 M–1
Direct, KaI = 7.1 (± 1.5) × 104 M–1

Palmitic acid (100-400 nM)
Normal HSA
Glycated HSA

r = 0.926 (n = 6)
r = 0.936 (n = 6)

Direct, KaI = 3.1 (± 0.6) × 105 M–1
Direct(?)c, KaI = 2.6 (± 2.6) × 107 M–1

Stearic acid (10-80 nM)
Normal HSA
Glycated HSA

r = 0.890 (n = 7)
r = 0.973 (n = 8)

Direct, KaI = 6.5 (± 1.5) × 105 M–1
Direct, KaI = 3.0 (± 0.3) × 106 M–1

a. The correlation coefficients are those obtained for a plot made according to Equation (1).
b. The values in parentheses represent a range of ± 1 S.D. A mixed mode interaction (e.g., direct competition plus a positive
allosteric effect) was indicated in plots made according to Equation (1) by an initial decrease and then gradual increase in the
retention factor for the injected drug as the concentration of fatty acids in the mobile phase was increased. A decrease in the
retention factor for the drug when there was an increase in the concentration of the fatty acids could be produced by either a net
negative allosteric effect or direct competition; in this study, the overall fit of the results to Equation (1) generally suggested that
direct competition was present in most of these cases. In these latter cases, the apparent value of KaI for the fatty acid, as obtained
by using Equation (1), is provided.
c. The correlation coefficient obtained in this case was not significant at the 95% confidence level or, in the case of palmitic acid and
glycated HSA, the resulting value of KaI had a level of uncertainty that made it difficult to determine if direct competition was
present in the given system. The symbol “(?)” indicates that the variation in the data was too large or the change in the retention
factor was too small to obtain a reliable determination of exact type of interaction that was present or of the corresponding value
of KaI in the case of direct competition.
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Figure 4. Observed change in the
retention factor (k) for gliclazide (●),
tolbutamide (▲) and acetohexamide
(♦) on HPLC columns containing
immobilized (a) normal HSA or (b)
glycated HSA and in the presence
of mobile phases containing various
concentrations of myristic acid. All
values shown in this figure are the
averages of three replicates and had
relative standard deviations in the
range of ±0.1–1.6%.

interactions on the normal HSA column for all of the drugs
but gave confirmed or possible direct competition with
these drugs on the glycated HSA column. These differences again indicated that glycation can affect the types of
interactions that occur between fatty acids and sulfonylurea drugs, even at low fatty acid concentrations.
It was further possible to use Equation (1) and the bestfit parameters of the plots for systems found to have direct competition to estimate the overall value of KaI for each
fatty acid at its site(s) of competition with an injected drug.
These values were obtained by finding the ratio of the
slopes to the intercepts for plots of 1/k versus [I]. The re-

sulting values of KaI are provided in Tables 3-5 and were in
the general range of 105-108 M–1. These results gave good
agreement with association equilibrium constants that
have been reported for the same fatty acids with normal
HSA in solution [33, 39].
A change in KaI was often seen for fatty acids when going from normal HSA to glycated HSA even in cases for
which similar types of interactions were seen between the
fatty acid and a sulfonylurea drug. For example, acetohexamide, tolbutamide and gliclazide all gave a decrease in retention in the presence of myristic acid and stearic acid on
both the normal HSA and glycated HSA columns and re-
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sults that were consistent with a direct competition model.
The KaI values obtained for myristic acid at its sites of competition with these drugs on normal HSA were in the range
of 4.1-6.4 ×106 M–1 and increased to 1.4-2.4 ×107 M–1 for glycated HSA. Stearic acid also showed an increase in affinity (KaI) that went from 0.65-1.0 ×106 M–1 for normal HSA
to 3.0-3.6 ×106 M–1 for glycated HSA. These values represented a net 3.1- to 3.8- fold increase in affinity for myristic acid when using glycated HSA and a 3.3- to 4.9-fold
increase in affinity for stearic acid, with all of these differences being significant at the 95% confidence level.
Conclusion
Binding studies conducted by ultrafiltration and in the
presence of various fatty acids demonstrated that an increase free drug concentration, or weaker binding, generally occurred for both normal HSA and glycated HSA as
the concentration of fatty acids was increased. Such an effect could be due to direct competition or negative allosteric interactions between the fatty acids and drugs. The
only exception noted was for gliclazide in the presence of
oleic acid and normal HSA, for which an increase in overall binding was noted, as could be produced through a positive allosteric effect. Small or moderate changes in binding were found to be produced by lauric acid, myristic
acid and stearic acid, while linoleic acid and palmitic acid
gave moderate-to-large changes in binding. Oleic acid gave
small-to-moderate increases in free drug concentrations for
all of the tested drugs in the presence of glycated HSA and
for tolbutamide in the presence of normal HSA; however, a
large increase in free drug concentration for acetohexamide
was seen in the presence of oleic acid and normal HSA.
Chromatographic columns containing normal HSA or
glycated HSA were next used to examine in more detail
the effects of glycation on the interactions between common sulfonylurea drugs and fatty acids on this protein.
Relatively low fatty acid concentrations were employed in
this part of the study to emphasize the initial, high affinity interactions that occurred as fatty acids were added to
the system. Although similar overall changes in retention
were seen for most combinations of drugs and fatty acids,
some of these systems followed a direct competition model
while others involved a mixed-mode interaction between
the drugs and fatty acids under the conditions used in
this study. There were some cases in which differences occurred in the interaction mechanism between normal HSA
and glycated HSA (e.g., as seen for all of the drugs with linoleic acid). Even for those systems in which the same general type of interaction was present, changes were observed
in the affinity of the fatty acids at their sites of competition
with the drugs. This latter effect was noted for myristic acid
and stearic acid with all of the investigated drugs.
These results confirmed that glycation, as a result of the
metabolic changes that occur during diabetes, can alter the
binding of drugs and fatty acids with HSA. In addition, it
was found that changes in the levels of fatty acids, as can
also take place in diabetes, can further alter these interactions through various mechanisms. Together, this research
demonstrates the importance of considering how changes
in the concentrations and types of metabolites (e.g., in this
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case, glucose and fatty acids) can alter the function of a
protein such as HSA and its ability to interact with drugs
or other agents. These effects, in turn, may alter the nonbound fraction of a drug or solute, thus affecting the apparent activity and ability of this drug or solute to bind with
other proteins or receptors and to cross cell membranes
[11-14, 19-25]. As a result, experiments like those described
in this report are expected to gain in importance as greater
emphasis is placed on personalized medicine, or on the
role that a disease state and metabolic changes may play on
the customization of treatment for patients [14, 24, 48, 49].
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